AIDS Therapies (3TC)

Emory Patent for Epivir Claimed To Be Invalid

Published in AIDS Weekly, October 28th, 1996

Biochem Pharma Inc., Laval, Quebec, Canada, filed a response to a patent infringement suit brought by Emory University, Atlanta, Georgia. According to a company statement:

BioChem Pharma discovered Epivir/3TC (lamivudine) for the treatment of HIV/AIDS. Dr. Francesco Bellini, BioChem Pharma, welcomed the opportunity to have the patent issue settled through the U.S. legal system. "The federal courts provide us with the appropriate forum to finally put to rest Emory University's baseless claims to 3TC. Their action does a grave disservice to the late Dr. Belleau and all of the brilliant and dedicated scientists, who pioneered this discovery, which is currently...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry